LCAT and kidney disorder: Renal disease patients show significantly reduced plasma HDL-C, APOA-I, serum PON1 protein concentration, PON1 arylesterase/ paraoxonase activity, and LCAT activity [131], indicating the impaired interactions of PON1 with APOAI and LCAT in dysfunctional HDL in these patients.